Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort.
Breast Cancer Res Treat. 2014.
PMID: 24781971
Free PMC article.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2026 | 0 |
Search Results
21 results
Results by year
Citations
5
articles
found by citation matching
Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study.
Breast Cancer Res. 2021.
PMID: 33865453
Free PMC article.
Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort.
Am J Clin Nutr. 2015.
PMID: 26354532
Search results
Page 1
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.
Breast Cancer Res Treat. 2008 Jan;107(1):103-11. doi: 10.1007/s10549-007-9523-x. Epub 2007 Feb 27.
Breast Cancer Res Treat. 2008.
PMID: 17333341
Free PMC article.
It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N coh …
It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to …
Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study.
Breast Cancer Res. 2021 Apr 17;23(1):47. doi: 10.1186/s13058-021-01425-8.
Breast Cancer Res. 2021.
PMID: 33865453
Free PMC article.
BACKGROUND: Menopausal hormone therapy (MHT) is a risk factor for breast cancer (BC). Evidence suggests that its effect on BC risk could be partly mediated by mammographic density. ...METHODS: We used data from a case-control study nested within the Fr …
BACKGROUND: Menopausal hormone therapy (MHT) is a risk factor for breast cancer (BC). Evidence suggests that its …
Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort.
Breast Cancer Res Treat. 2014 Jun;145(2):535-43. doi: 10.1007/s10549-014-2934-6. Epub 2014 Apr 30.
Breast Cancer Res Treat. 2014.
PMID: 24781971
Free PMC article.
Questions remain on how the excess risk of breast cancer associated with menopausal hormone therapy (MHT) evolves after treatment stops. ...Our results suggest residual increases in breast cancer risk several years after MHT cessation, wh …
Questions remain on how the excess risk of breast cancer associated with menopausal hormone therapy (MHT) evolve …
Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
Int J Cancer. 2016 Nov 15;139(10):2193-200. doi: 10.1002/ijc.30282. Epub 2016 Jul 30.
Int J Cancer. 2016.
PMID: 27451078
We investigated a potential interaction between BMI and vitamin D supplementation on breast cancer risk while considering an already reported interaction between vitamin D supplementation and menopausal hormone therapy (MHT) use. Vitamin D supplementat …
We investigated a potential interaction between BMI and vitamin D supplementation on breast cancer risk while considering an a …
Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.
Int J Cancer. 2005 Apr 10;114(3):448-54. doi: 10.1002/ijc.20710.
Int J Cancer. 2005.
PMID: 15551359
Most epidemiological studies have shown an increase in breast cancer risk related to hormone replacement therapy (HRT) use. A recent large cohort study showed effects of similar magnitude for different types of progestogens and for different rou …
Most epidemiological studies have shown an increase in breast cancer risk related to hormone replacement therapy …
Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort.
Am J Clin Nutr. 2015 Oct;102(4):966-73. doi: 10.3945/ajcn.114.104323. Epub 2015 Sep 9.
Am J Clin Nutr. 2015.
PMID: 26354532
Free article.
OBJECTIVE: Our objective was to investigate the association between postmenopausal breast cancer risk and current or past vitamin D supplementation overall and according to the use of menopausal hormone therapy (MHT). DESIGN: Between 1995 and 2008, 248 …
OBJECTIVE: Our objective was to investigate the association between postmenopausal breast cancer risk and current or past vita …
Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
J Clin Oncol. 2009 Nov 1;27(31):5138-43. doi: 10.1200/JCO.2008.21.6432. Epub 2009 Sep 14.
J Clin Oncol. 2009.
PMID: 19752341
Free PMC article.
PURPOSE: To investigate whether the relation between estrogen-progestagen menopausal hormone therapy (EP-MHT) and breast cancer risk varies according to the delay between menopause onset and treatment initiation. ...Longer durations of EP-MHT use were …
PURPOSE: To investigate whether the relation between estrogen-progestagen menopausal hormone therapy (EP-MHT) and breast …
Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort.
Eur J Cancer Prev. 2010 Mar;19(2):120-5. doi: 10.1097/CEJ.0b013e3283354918.
Eur J Cancer Prev. 2010.
PMID: 20042864
Metabolic syndrome, including low HDL cholesterol, has been associated with an increased breast cancer risk, whereas little is known of the relationship with total cholesterol. Cox proportional hazards regression models were performed to evaluate the association bet …
Metabolic syndrome, including low HDL cholesterol, has been associated with an increased breast cancer risk, whereas little is …
Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort.
Int J Cancer. 2016 May 15;138(10):2415-27. doi: 10.1002/ijc.29987. Epub 2016 Feb 4.
Int J Cancer. 2016.
PMID: 26756677
Breast cancer is the most frequently diagnosed cancer among women worldwide. Breast cancer risk factors have been widely explored individually; however, little is known about their combined impact. We included 67,634 women from the French E3N …
Breast cancer is the most frequently diagnosed cancer among women worldwide. Breast cancer risk factors h …
Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women.
J Clin Oncol. 2017 Oct 1;35(28):3230-3239. doi: 10.1200/JCO.2016.71.4337. Epub 2017 Jul 14.
J Clin Oncol. 2017.
PMID: 28708471
Purpose To assess whether bisphosphonate (BP) use is associated with decreased breast cancer incidence in a cohort of postmenopausal women. Methods The study population included 64,438 postmenopausal women participating in the French E3N (Etude Epidemi …
Purpose To assess whether bisphosphonate (BP) use is associated with decreased breast cancer incidence in a cohort of p …
Cite